Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23389099 | 1.00 | KDM2B (0.41) | KDM2BEPHX2HRH3DDR1LIPE | |
| SCHEMBL25993535 | 0.87 | KDM2B (0.46) | KDM2BEPHX2HRH3DDR1LIPE | |
| SCHEMBL25987838 | 0.82 | L3MBTL1 (0.36) | EPHX2 | |
| SCHEMBL23389187 | 0.81 | KDM2B (0.47) | KDM2BEPHX2HRH3DDR1LIPE | |
| SCHEMBL23389185 | 0.81 | KDM2B (0.47) | KDM2BEPHX2HRH3DDR1LIPE | |
| SCHEMBL25987824 | 0.79 | CHRM4 (0.42) | KDM2BEPHX2 | |
| SCHEMBL23389211 | 0.78 | EPHX2 (0.42) | KDM2BEPHX2HRH3 | |
| SCHEMBL23389214 | 0.78 | EPHX2 (0.42) | KDM2BEPHX2HRH3 | |
| SCHEMBL23419111 | 0.75 | KMT2A (0.52) | EPHX2MEN1KMT2AATM | |
| SCHEMBL23389188 | 0.75 | KMT2A (0.52) | EPHX2MEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263366-A2 | CASPASE 6 INHIBITORS AND USES THEREOF | SHANGPHARMA INNOVATION INC. | 2025-08-21 | — | — | US | disclosed |
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-06-29 | — | — | US | disclosed |
| WO-2021102361-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | CASP6, CASP1, CASP10 | KDM2B 3814/4885EPHX2 3551/4885HRH3 4241/4885 |
| US-20250263366-A2 | CASPASE 6 INHIBITORS AND USES THEREOF | CASP6, CASP1, CASP10 | KDM2B 3814/4885EPHX2 3551/4885HRH3 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.